EHL Bio Co., Ltd.   Report issue

For profit Phase 1 Phase 2
Founded: Korea, Republic of (1984)

Organization Overview

First Clinical Trial
2016
NCT02888704
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

EHL Bio Co., Ltd.

Active Ingredients

Drugs in Phase 2 Trials (1)

allogeneic adipose derived mesenchymal stem cell (1 trial)

Drugs in Phase 1 Trials (2)

autologous mesenchymal stem cells (1 trial)

kdstem. (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Dermatitis (Phase 2)

Dermatitis, Atopic (Phase 2)

Eczema (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 3